nach oben

Erschienen in:

01.08.2019 | Clinical study

No increased risk of UTIs with SGLT-2 inhibitor use

Erschienen in: Reactions Weekly | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Excerpt

Initiation of sodium-glucose transporter-2 (SGLT-2) inhibitors does not appear to increase the risk of urinary tract infections (UTIs) compared with the initiation of dipeptidyl peptidase-4 (DPP-4) inhibitors (CD26 antigen inhibitors) or glucagon-like peptide-1 receptor (GLP-1) agonists in patients with type-2 diabetes mellitus (T2DM), according to findings of a US study published in Annals of Internal Medicine.1 …

Dave CV, et al. Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Severe Urinary Tract Infections: A Population-Based Cohort Study. Annals of Internal Medicine : 30 Jul 2019. Available from: URL: http://dx.dopi.org/10.7326/M18-3136

Filion KB, et al. Sodium-Glucose Cotransporter-2 Inhibitors and Severe Urinary Tract Infections: Reassuring Real-World Evidence. Annals of Internal Medicine : 30 Jul 2019. Available from: URL: http://dx.doi.org/10.7326/M19-1950

Titel: No increased risk of UTIs with SGLT-2 inhibitor use
Publikationsdatum: 01.08.2019
Verlag: Springer International Publishing
Erschienen in: Reactions Weekly / Ausgabe 1/2019
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-019-65767-7

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

No increased risk of UTIs with SGLT-2 inhibitor use

Excerpt

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2019

Amiodarone

Alteplase/dabigatran-etexilate/idarucizumab

Citalopram

Ipilimumab/nivolumab

Valproate-semisodium

Gimeracil/oteracil/tegafur/oxaliplatin/paclitaxel